Navigation Links
Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
Date:11/4/2009

d are the focus of our ongoing research funded by a Transformational Medical Technologies Initiative contract to study the potential of these agents as broad spectrum viral hemorrhagic fever therapeutics."

PS, a lipid molecule normally found only on the inside of cell membranes, becomes exposed on the outside of the membranes of viruses and virally infected cells. A rapidly growing body of published scientific research confirms that exposed PS is directly involved in the pathogenesis of many serious infectious diseases. Exposed PS enables viruses to evade immune recognition and dampens the body's normal responses to infection. By masking the exposed PS, PS-targeting antibodies are believed to block these effects, allowing the body to develop a robust immune response to the pathogen.

Peregrine's PS-targeting antibodies have been shown to help clear infectious virus from the bloodstream and to induce antibody-dependent cellular cytotoxicity. PS is exposed on the outer membrane of cells infected with a wide range of viruses, including HIV, influenza, herpes simplex viruses, hemorrhagic fever viruses, cytomegalovirus (CMV), measles and members of the smallpox and rabies virus families. Targeting PS thus provides a broad platform for treating viral infections. Because the PS target is host-derived rather than pathogen-derived, PS-targeting antibodies are also expected to be much less susceptible to the viral genomic mutations that lead to anti-viral drug resistance.

Bavituximab, which is Peregrine's most advanced PS-targeting antibody, is currently being studied in a clinical trial for the treatment of patients co-infected with HCV and HIV. Phase I studies in HCV patients showed that bavituximab was well tolerated and it exhibited encouraging signs of anti-viral activity.

Under a major biodefense initiative funded by the Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI),
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements
2. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
3. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
4. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
5. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
6. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
7. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
8. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
9. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
10. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
11. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... CareCentrix, Inc ., the nation,s leading provider ... that it has been awarded Health Utilization Accreditation ... organization that establishes quality standards for the health ... trained, qualified clinical personnel conduct and oversee the ... appeals process is in place, and that medical ...
(Date:12/16/2009)... Dec. 16 /PRNewswire/ -- Sanofi ... Group, announced today that it has entered ... Syntiron to develop and commercialize its prophylactic ... Staphylococcus aureus or MRSA. MRSA ... humans, sometimes referred to as multidrug-resistant ...
(Date:12/16/2009)... Illinois Disappointed By Senate Vote Against Lower Prescription ... -- The U.S. Senate on Tuesday night rejected ... Care Act that would help make prescription drugs ... legal importation of lower priced drugs from abroad. ... sponsored by Senators Dorgan, Snowe, McCain, Grassley and ...
Breaking Medicine Technology:CareCentrix Receives URAC Health Utilization Management Accreditation 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4AARP Illinois Key Vote News Alert 2Sundia Appoints Charles D Maher as Senior Vice President of Sales and Marketing 14481 1Sundia Appoints Charles D Maher as Senior Vice President of Sales and Marketing 14481 2Department of Energy Grants BlueFire Approval for Site Change 14479 1Department of Energy Grants BlueFire Approval for Site Change 14479 2Department of Energy Grants BlueFire Approval for Site Change 14479 3Department of Energy Grants BlueFire Approval for Site Change 14479 4Cynosure to Announce Third Quarter 2009 Financial Results on October 27 5509 1Cynosure to Announce Third Quarter 2009 Financial Results on October 27 5509 2
... tolerance observed in Genotype,1 patients support development ... 21, 2007 /PRNewswire/ -- Intarcia Therapeutics,Inc., a ... of final results from a Phase 2 ... and ribavirin to,omega interferon alone in treatment-naive ...
... Function and Treatment of Anxious,and Painful Physical ... -- Data,suggest that patients with generalized anxiety ... improved,ability to perform everyday activities at home, ... pill. These improvements in global,functioning were the ...
Other Medicine Technology:Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 2Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 3Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 4Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 2Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 3Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 4Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 5Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 6
(Date:12/17/2009)... service gets businesses listed on search engines like Google Local and ... affordable Web presence with SEO Local Registration service offered by New ... ... LA (PRWEB) December 17, 2009 -- In order to be competitive ... website or a listing on a local map section in a ...
(Date:12/17/2009)... law firm, litigators of complex personal injury and insurance cases, recognized ... ... Tulsa, OK (Lexis Nexis) December 17, 2009 -- Jody ... of experience handling personal injury and insurance coverage disputes, has been ... attorneys in the state of Oklahoma for 2009-2010., , ,Only five ...
(Date:12/16/2009)... Calif., Dec. 17 If proposed health ... standards in the employer-based insurance system. Approximately 18.4 ... age of 65 rely upon employer-based insurance for ... and Senate versions of reform legislation entail specific ... majority of employees work for firms that currently ...
(Date:12/16/2009)... Dec. 16 Smart Balance, Inc. (Nasdaq: ... has authorized a two-year stock repurchase program of up ... repurchase program demonstrates the confidence we have in the ... deliver long-term value for all of our shareholders, while ... said Stephen Hughes, Smart Balance, Inc. Chairman and Chief ...
(Date:12/16/2009)... December 16, 2009 -- Every year in the United ... 57,000 patients die of the disease, making it the ... after lung cancer. , As researchers and clinicians fervently ... simultaneously generating thousands of studies producing more and more ... of cancer and genetics at Case Western Reserve University ...
Breaking Medicine News(10 mins):Health News:New Orleans Based Internet Marketing Is Helping Small Businesses Get a Chance to Shine On the Web 2Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3
... Episodes of the Oprah Winfrey ... Show on November 1 and November 5 -, SILVER SPRING, ... has a direct effect our waistlines, but how aware are we,that ... quality of,sleep actually impact our body,s physical age? Discovery Health,s chief,medical ...
... five,successful years of steady growth, ReBuilder Medical Technologies, ... celebrating five years of,continued operations by shipping out ... 100,000 orders by the end of 2008., ... for Diabetic Peripheral Neuropathy has been a steady,winner ...
... can help complement a healthy diet and lifestyle, but,consumers ... says the,new edition of a Harvard Medical School report, ... know., The immune system defends the body against ... claim their products,"support" immunity. But so far, there is ...
... Palmer with critical access control features and ... support for bandwidth-intensive applications, WALTHAM, Mass. ... Colubris Networks, the leading global provider of,intelligent wireless LANs ... College of Chiropractic, the largest,chiropractic college in the world, ...
... shows that religion and spirituality are linked to positive ... on people with life threatening diseases. A new study ... many individuals with disabilities adjust to their impairments and ... the study, persons facing impending death may use religion ...
... the scientific symposium of the Cardiovascular Research Foundation (CRF), show ... (SSO 2 ) can reduce the amount of damaged heart ... or restoration of blood flow to the heart with angioplasty ... of infarction, or damaged heart muscle caused by the death ...
Other Medicine News:Health News:Dr. Oz and Dr. Roizen Prove That Aging Is Actually Reversible in You: Staying Young on Discovery Health 2Health News:Dr. Oz and Dr. Roizen Prove That Aging Is Actually Reversible in You: Staying Young on Discovery Health 3Health News:ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment 2Health News:ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment 3Health News:Harvard Medical School: Healthy Lifestyle Will Boost Your Immune System Better Than a Handful of Supplements 2Health News:Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses 2Health News:Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses 3Health News:Religion and healthcare should mix, MU study says 2
ASAP™ Automated Biopsy System with Channel Cut™ Needle....
The Easy Core Biopsy Device offers exceptional performance in automated core biopsy, and provides excellent ergonomics and increased notch size....
Incontinence Pessaries...
Incontinence Pessaries...
Medicine Products: